Christopher J. Schaber Ph.D.
Net Worth

Last updated:

What is Christopher J. Schaber Ph.D. net worth?

The estimated net worth of Dr. Christopher J. Schaber Ph.D. is at least $14,916,968 as of 18 May 2022. He owns shares worth $331,568 as insider and has received compensation worth at least $14,585,400 in Soligenix, Inc..

What is the salary of Christopher J. Schaber Ph.D.?

Dr. Christopher J. Schaber Ph.D. salary is $810,300 per year as Chairman, Chief Executive Officer & Pres in Soligenix, Inc..

How old is Christopher J. Schaber Ph.D.?

Dr. Christopher J. Schaber Ph.D. is 59 years old, born in 1966.

What stocks does Christopher J. Schaber Ph.D. currently own?

As insider, Dr. Christopher J. Schaber Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Soligenix, Inc. (SNGX) Chairman, Chief Executive Officer & Pres 90,095 $3.68 $331,568

What does Soligenix, Inc. do?

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

SNGX logo
SNGX
Soligenix, Inc.
$3.68

Christopher J. Schaber Ph.D. insider trading

Soligenix, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 20,000 $0.44 $8,860
Purchase
COMMON STOCK 7,000 $0.74 $5,180
Purchase
COMMON STOCK 10,000 $0.73 $7,270
Purchase
Common Stock 10,770 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 8,700 N/A N/A
Purchase
Common Stock 3,530 N/A N/A
Purchase
Common Stock Warrant 19,755 N/A N/A
Purchase
Common Stock 15,804 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Option
Common Stock 7,143 N/A N/A
Option
Common Stock Warrant 7,143 N/A N/A
Purchase
Common Stock Warrant 4,959 N/A N/A
Purchase
Common Stock 8,265 N/A N/A
Option
Option (Right to Buy) 7,815 N/A N/A
Option
Common Stock 7,815 N/A N/A
Purchase
Common Stock 9,523 N/A N/A
Purchase
Common Stock Warrants 7,143 N/A N/A
Purchase
Common Stock 9,900 N/A N/A
Purchase
Common Stock 79,051 N/A N/A
Purchase
Common Stock 100,000 N/A N/A
Purchase
Common Stock 212,766 N/A N/A

Soligenix key executives

Soligenix, Inc. executives and other stock owners filed with the SEC: